Danish Banks Stock News

Kreditbanken (CPSE:KRE) reported net profit margins of 41%, down from 44.9% a year earlier. Profit growth has declined over the past year following a prior five-year average of 19.5% annual earnings expansion. Shares now trade at DKK7,400, notably below the estimated fair value of DKK15,565.49. The company's P/E ratio of 8.6x stands lower than both its peer average of 11.1x and the European Banks industry average of 9.7x. Despite recent margin compression, the bank continues to offer...

Per Aarsleff Holding (CPH:PAAL B) has had a great run on the share market with its stock up by a significant 14% over...

Key Insights The projected fair value for TORM is kr.225 based on 2 Stage Free Cash Flow to Equity TORM's kr.139 share...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

DSV (CPSE:DSV) reported net profit margins of 5.3% for the recent year, a decrease from 7.1% last year, and experienced negative earnings growth despite an 8.7% annual earnings expansion over the past five years. Looking ahead, earnings are forecast to grow at 24.6% per year and revenue is projected to rise by 7.4% annually. Both figures are expected to outpace the broader Danish market. The stock trades at DKK1420.5, well below its estimated fair value of DKK2672.77. Its price-to-earnings...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

If you are eyeing Genmab’s stock right now, you are certainly not alone. After a sharp 6.2% rally over the past month, the stock has given up some of those gains with a -9.2% slip in the last week. But don’t let short-term swings distract you from the surprising longer-term resilience here. Genmab is still up 26.6% since January and has gained 22.8% over the past year, even as the wider biotech sector has had its share of shake-ups. What is driving all this movement? It has been a mix of...

Most readers would already know that UIE's (CPH:UIE) stock increased by 4.8% over the past month. We wonder if and what...

Ringkjøbing Landbobank (CPSE:RILBA) reported net profit margins of 55.7%, a slight decline from last year’s 56.9%. Earnings have grown at a robust 21.6% annually over the past five years but slipped into negative territory year-on-year. Revenue is forecast to rise 2.9% per year and earnings 1.4% annually, both trailing the Danish market growth rates. Despite these lower forward growth prospects, investors may be watching closely as the bank’s high-quality earnings profile and strong...

Embla Medical hf (CPSE:EMBLA) posted earnings forecast to grow at 14.51% per year, with revenue set to rise by 8.5% annually. Both figures are ahead of the Danish market’s expected growth. The company’s net profit margin edged up to 8.6% from 8.2% the year before. While the most recent year’s earnings growth came in at 11.7%, the broader five-year average sits at a robust 19.2% per year. Embla’s combination of faster-than-market growth and steadily improving profitability, coupled with a lack...

Key Insights Using the 2 Stage Free Cash Flow to Equity, NKT fair value estimate is kr.1,132 Current share price of...

If you’ve been watching Novo Nordisk stock and wondering whether it’s time to buy, sell, or simply hold steady, you’re definitely not alone. Over the past year, shares have tumbled by more than 50%, with a 44.4% decline so far this year alone. Even so, those longer-term investors who got in five years ago are still sitting on impressive gains of nearly 80%. That sharp reversal of fortune understandably has many folks scratching their heads and asking what’s driving the story right now, and is...

As Europe navigates a mixed economic landscape, with the pan-European STOXX Europe 600 Index slightly up amid dovish signals from the U.S. Federal Reserve and easing trade tensions, investors are keenly observing small-cap stocks for their potential resilience and growth opportunities. In such an environment, stocks with strong fundamentals—such as robust financial health, competitive positioning, and consistent earnings—can stand out as promising candidates for those looking to explore...

Alm. Brand (CPSE:ALMB) shares have been trading in a relatively tight range recently, with only minor moves seen over the past week and month. Investors watching the Danish insurer may be assessing its current valuation after steady, if unspectacular, returns this year. See our latest analysis for Alm. Brand. The share price has largely moved sideways lately, showing little volatility. However, the bigger story is Alm. Brand's impressive 40.7% total shareholder return over the past year and...

Sydbank (CPSE:SYDB) shares have delivered solid returns over the past year, rising 63% and outpacing many peers in the Danish banking sector. Investors watching for value might be curious about what is driving the momentum. See our latest analysis for Sydbank. After a year of strong total shareholder returns, Sydbank’s recent upward momentum has continued, with a 3.2% share price return over the past month. The longer-term total shareholder return of 62.5% for the year suggests sustained...

If you’ve been paying attention to Danske Bank lately, you’ve probably noticed there’s been plenty of action in its share price. Maybe you’re even wondering whether now is the moment to jump in or take some profits off the table. Over the past year, Danske Bank has delivered a remarkable 50.2% return, with gains standing at a powerhouse 230.9% for the past three years and nearly tripling over five years. Even in the shorter term, its year-to-date return is a striking 33.8%. While the 7-day...

As of October 2025, European markets have shown mixed performance, with the pan-European STOXX Europe 600 Index inching higher amid dovish signals from U.S. Federal Reserve officials and easing trade tensions between the U.S. and China. While major indices like France's CAC 40 have rallied, others such as Germany's DAX have faced declines, reflecting varied economic conditions across the region. In this context of fluctuating market dynamics, identifying undervalued stocks can be crucial for...

Recently released data indicates the Asia-Pacific mineral wool market is projected to grow at a 1.3% CAGR, reaching 15 million tons by 2035, with China accounting for nearly half of regional consumption and production, and Japan leading in market value. An especially large 37% increase in regional exports during 2024, driven primarily by China, highlights accelerating trade activity and solidifies the region’s growing importance for mineral wool producers like Rockwool. With rising...

ChemoMetec (CPSE:CHEMM) shareholders received some welcome news at the company’s recent annual general meeting, where a dividend of DKK 7 per share was approved. This move reflects management’s confidence in ChemoMetec’s financial strength and ongoing performance. See our latest analysis for ChemoMetec. ChemoMetec’s recent dividend announcement comes after a robust stretch for shareholders, with the stock’s 1-year total return topping 61.7%. Momentum has accelerated noticeably in recent...

Jyske Bank (CPSE:JYSK) has raised its earnings guidance for 2025, expecting net profit to reach DKK 4.9 to 5.3 billion and earnings per share between DKK 77 and 84, up from previous projections. See our latest analysis for Jyske Bank. Jyske Bank’s upbeat 2025 profit guidance comes as its shares are up 42.87% year-to-date. The company has delivered a total shareholder return topping 43% over the past year and almost 300% over five years, helping build strong upward momentum. If you’re...

Coloplast (CPSE:COLO B) has announced that interim CEO Lars Rasmussen will not stand for re-election to the Board at the upcoming annual general meeting in December. The search for a permanent CEO continues. See our latest analysis for Coloplast. Leadership shifts like these tend to put a spotlight on Coloplast’s next chapter, which investors are weighing against a challenging year. While recent days saw a modest 3.54% 7-day share price return, the 1-year total shareholder return has slumped...

Shares in Novo Nordisk (CPSE:NOVO B) moved sharply this week after President Trump announced plans to lower U.S. prices for weight-loss and diabetes drugs like Ozempic. The announcement prompted heightened volatility and renewed investor questions about the company’s future profit outlook. See our latest analysis for Novo Nordisk. Novo Nordisk’s share price has been on a roller coaster, down over 46% year-to-date and recently tumbling after U.S. policy signals on drug pricing, despite...

At its Annual General Meeting held on 9 October 2025, ChemoMetec A/S approved a dividend distribution of DKK 7 per share of nominal value DKK 1. This move highlights the company's focus on returning capital to shareholders and may signal confidence in its ongoing financial stability. We'll explore how the approved dividend underscores ChemoMetec's shareholder priorities and affects its overall investment narrative. Find companies with promising cash flow potential yet trading below their...

Københavns Lufthavne (CPSE:KBHL) recently announced plans for a major board reshuffle, as three current directors are set to resign following the extraordinary general meeting on 23 October and new members are proposed to join. See our latest analysis for Københavns Lufthavne. The upcoming shake-up in Københavns Lufthavne’s leadership comes after a year of solid momentum, highlighted by an 11.7% share price return year to date and a standout 69.2% total shareholder return over the past...